Edward Wenge Wang, M.D., Ph.D.
Edward Wenge Wang, M.D., Ph.D., is the section chief of the Gynecologic Oncology and assistant professor in the Department of Medical Oncology & Therapeutics Research, specializing in gynecologic oncology.
Dr. Wang earned his undergraduate degree in medicine, followed by a Master of Science degree in immunology and a Ph.D. in tumor immunology, from Harbin Medical University in Harbin, China. He completed postdoctoral research at Columbia University Vagelos College of Physicians and Surgeons in New York, before moving to Philadelphia to serve as a research associate at the Howard Hughes Medical Institute, while also serving as senior research investigator at the University of Pennsylvania School of Medicine.
After a brief time as director of projects for the Hershey Cancer Institute at Penn State University Hershey Medical College, Dr. Wang successfully completed postgraduate training with an internship and residency in internal medicine at Montefiore Mount Vernon Hospital in New York, and Banner-University Medical Center in Phoenix, respectively. He completed his hematology-oncology fellowship training at Penn State Hershey Medical College in Pennsylvania.
Dr. Wang has authored 45 scholarly articles and has been an invited lecturer at symposiums and conferences across the country. He is a principal investigator of several clinical trials. He is running a Molecular and Cellular Laboratory in the City of Hope Biomedical Research Center at Beckman Research Institute of City of Hope for translational research. His research interests include: Targeting intrinsic and extrinsic cell death pathways by developing novel therapeutics for cancer treatment. Most recently, he has developed an oncolytic virus that can specifically replicate in and lyse gynecological cancer cells.
In 2002, Dr. Wang received the AACR/AFLAC Scholar-in-Training Award at the American Association for Cancer Research Annual Meeting in San Francisco.
Dr. Wang is the recipient of several intramural and extramural grants including an NIH K12 career development award in 2018, an NIH/NCI R21 grant in 2021, for ovarian cancer research a Margaret E. Early Trust Award in 2022, and a City of Hope drug development award in 2022, he owns three patents that cover his significant discoveries.
Duarte Cancer Center
Duarte, CA 91010
2016, American Society of Clinical Oncology Board certified
2016, American Society of Hematology Board eligible
2013, American Board of Internal Medicine certified
1988, B.M., Medicine, Habin Medical University, Harbin, Heilongjiang, China
1991, M.S., Immunology, Harbin Medical University, Harbin, Heilongjiang, China
1994, Ph.D., Tumor Immunology, Harbin Medical University, Heilongjiang, China
2013-2016, Fellow, Hematology/Oncology, Penn State Hershey Medical Center, Hershey, PA
2011-2013, Resident, Categorical Internal Medicine, Banner University Medical Center, University Medical Center, Phoenix, AZ
2010-2011, Intern, Categorical Internal Medicine, Montefiore Mount Vernon Hospital, Mount Vernon, NY
2023-present, Chief of Gynecologic Oncology, Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
2019-present, Associate Editor, Frontiers in Oncology: Cancer Molecular Targets and Therapeutics, a peer-reviewed professional journal
2018-present, Editor, Cancer Biology and Therapy, a peer-reviewed professional journal
2016-present, Director of Gynecologic Laboratory for Translational Research, Department of Medical Oncology and Therapeutics, Beckman Research Institute, City of Hope
2016-present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
2017-2021, NIH/NCI: K12 Fellow, Paul Calabresi Career Development Award for Clinical Oncology
2010, Director of Research Projects, Cancer Institute, Penn State Hershey Medical Center, Hershey, PA
2004-2010, Senior Research Investigator, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
2001-2004, Research Associate, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, PA
1999-2001, Postdoctoral Research Scientist, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
1997-1999, International Special Medical Investigator, Japan Society for Promotion of Science, Osaka University Medical School, Osaka, Japan
1994-1997, Postdoctoral Research Fellow, Department of Experimental Hematology, Beijing Medical Academy Institute of Radiology, Beijing, China
Member, American Society of Clinical Oncology
Member, American Society of Hematology
Member, American Association Cancer Research
-
Wei CH, Shehayeb S, Santiago NL, Kruper L, Han E, Wang E, Cristea M, Rodriguez-Rodriguez L, Yost SE, Stewart D. BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute. PLoS One. 2023;18(6):e0286998.
-
Senguttuvan RN, Wei C, Raoof M, Dellinger TH, Wang EW. Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma. J Clin Med. 2023;12(11).
-
O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, Doger de Speville Uribe B, Hegg R, Ortuzar Feliu W, Ancukiewicz M, Lugowska I. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022;40(7):762-71.
-
Ladbury C, Li R, Shiao J, Liu J, Cristea M, Han E, Dellinger T, Lee S, Wang E, Fisher C, Chen YJ, Amini A, Robin T, Glaser S. Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging? Gynecol Oncol. 2022;164(1):39-45.
-
Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, Kebria M, Hakim A, Ruel N, Stewart DB, Wang EW, Paz BI, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. JCO Precis Oncol. 2022;6:e2100239.
-
Yue E, Yang G, Yao Y, Wang G, Mohanty A, Fan F, Zhao L, Zhang Y, Mirzapoiazova T, Walser TC, Rodriguez-Rodriguez L, Fong Y, Salgia R, Wang EW. Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment. Cancers (Basel). 2021;13(17).
-
Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik J, Korzekwa K, Ruth K, White K, Cooper HS, Ross EA, Zhou L, El-Deiry WS. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2021;20(1):e43-e52.
-
Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel). 2021;13(11).
-
Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021;12(1):3039.
-
Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L. Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. J Clin Med. 2020;9(9).